
About Siren Biotechnology
Siren Biotechnology is a Healthcare company based in San Francisco (United States) founded in 2021 by Nicole K Paulk. Developer of gene therapies for cancer treatments. Siren Biotechnology has raised $19.61 million across 1 funding round. Its chief executive, as recorded, is Nicole K Paulk. Siren Biotechnology offers products and services including AAV Immuno-Gene Therapy. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Siren Biotechnology was founded in 2021 and is headquartered in San Francisco, United States. Focus is placed on the biotechnology sector, where gene therapies for cancer treatments are developed. AAV-based gene therapy and cytokine immunotherapy are provided to stimulate immediate anti-tumor responses across multiple indications. Operations center on advancing these therapies for clinical applications in oncology.
- Headquarters San Francisco, United States
- Founders Nicole K Paulk
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website sirenbiotechnology.com
- Social LinkedIn X Facebook YouTube
- Total Equity Funding$19.61M (USD)
in 1 rounds
- Latest Funding Round$19.61M (USD), Series B
Apr 2024
Products & Services of Siren Biotechnology
Siren Biotechnology offers a comprehensive portfolio of products and services, including AAV Immuno-Gene Therapy.
Combines AAV vectors and cytokines to treat solid tumor cancers.
Apps and channels of Siren Biotechnology
its YouTube channel Siren Biotechnology has 36 subscribers.
Funding Insights of Siren Biotechnology
Siren Biotechnology has successfully raised a total of $19.61M through 1 strategic funding round. The most recent funding activity was a Series B round of $19.61 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $19.61M
- Total Rounds 1
- Last Round Series B β $19.61M
- First Round $19.61M
(Apr 2024)
All 1 funding rounds of Siren Biotechnology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2024 | $19.61M | Series B | β | β | β |
People of Siren Biotechnology
3 people are tracked at Siren Biotechnology (3 in leadership).
| Name | Role | Group |
|---|---|---|
Nicole K Paulk | Founder & CEO | Leadership |
Nathalie Clement 🇺🇦 | VP Vector Development for Translational Gene Therapies | Leadership |
Nicole K. Paulk, PhD | CEO, Founder, President | Leadership |
Complete people profiles for Siren Biotechnology
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Siren Biotechnology
2 dated milestones of Siren Biotechnology across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Siren Biotechnology is founded.
- Funding First funding round of $19.6M.
Competitors of Siren Biotechnology
Siren Biotechnology has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Siren Biotechnology
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Siren Biotechnology
The website of Siren Biotechnology (sirenbiotechnology.com) receives about 3K visits a month.
- Monthly visits3K
▼ 26.8% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Siren Biotechnology (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Siren Biotechnology
Complete news archive for Siren Biotechnology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Siren Biotechnology
Siren Biotechnology was founded in 2021 and raised its 1st funding round 3 years after it was founded.
Siren Biotechnology is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Nicole K Paulk is the CEO of Siren Biotechnology, as recorded in our data. They have also founded this company.
Siren Biotechnology is a funded company, having raised a total of $19.61M across 1 funding round to date. The company's 1st funding round was a Series B of $19.61M, raised on Apr 2024.
Siren Biotechnology was founded in 2021 and is headquartered in San Francisco, United States. Focus is placed on the biotechnology sector, where gene therapies for cancer treatments are developed. AAV-based gene therapy and cytokine immunotherapy are provided to stimulate immediate anti-tumor responses across multiple indications. Operations center on advancing these therapies for clinical applications in oncology.
Siren Biotechnology offers AAV Immuno-Gene Therapy.
